A nurse clinician-scientist and professor at the University of Toronto, in Canada, is being honored for her work in developing…
Articles by Marisa Wexler, MS
The American Red Cross and the Sickle Cell Disease Association of Illinois (SCDAI) recently joined a national distributor of propane,…
Bluebird Bio has struck a deal with Medicaid in the state of Michigan to allow eligible people with…
Starting in 2025, the U.S. Department of Health and Human Services (HHS) will introduce a pricing model that aims to…
England’s National Health Service (NHS) is introducing a new genetic test that seeks to make it safer for people with…
Comer Children’s Hospital at the University of Chicago will be one of the first centers in the U.S.
Most sickle cell disease (SCD) patients treated with the gene therapy Lyfgenia (lovotibeglogene autotemcel) in clinical trials were free…
Health regulators in the Kingdom of Bahrain have approved the gene-editing therapy Casgevy (exagamglogene autotemcel) to treat people with…
The Phase 1/2 BEACON trial, which is testing the gene-editing cell therapy BEAM-101 in people with sickle cell disease…
An advisory committee to the U.S. Food and Drug Administration (FDA) has completed its meeting on exa-cel — formally exagamglogene…